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OBJECTIVE—To compare the associations of nontraditional (fructosamine, glycated albu-
min, 1,5-anhydroglucitol [1,5-AG]) and standard (fasting glucose, HbA1c) glycemic markers
with common microvascular conditions associated with diabetes mellitus.
RESEARCHDESIGNANDMETHODS—Weconductedacross-sectionalstudyof1,600
participants (227 with a history of diabetes and 1,323 without) from the Atherosclerosis Risk in
Communities (ARIC) Study, a community-based population. We conducted logistic regression
analysesoftheassociationsofdiabetes-speciﬁctertilesoffructosamine,glycatedalbumin,1/(1,5-
AG), fasting glucose, and HbA1c with prevalence of chronic kidney disease, albuminuria, and
retinopathy after adjustment for demographic, clinical, and lifestyle variables.
RESULTS—We observed signiﬁcant positive trends in the associations of each marker with
albuminuria and retinopathy, even after accounting for demographic, clinical, and lifestyle fac-
tors (all P trends ,0.05). The associations with chronic kidney disease were similar in direction
but were only signiﬁcant for higher glycated albumin (P trend = 0.005), fructosamine (P trend =
0.003), and HbA1c (P trend = 0.005) values. After further adjustment for HbA1c, glycated albu-
min and fructosamine remained signiﬁcantly or borderline signiﬁcantly associated with the
microvascular outcomes.
CONCLUSIONS—In cross-sectional analyses, two serum markers of glycemia—glycated
albumin and fructosamine—are as, or more strongly, associated with microvascular conditions
as HbA1c. These markers may be useful in settings where whole blood is not available. Whether
they might complement or outperform HbA1c in terms of long-term predictive value requires
further investigation.
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bA1c is the gold-standard measure
for assessment of glycemic control
andhasrecentlybeenrecommended
for use in the diagnosis of diabetes (1).
HbA1c results from the glycation of he-
moglobin in erythrocytes and represents
long-term(2–3months)glycemia.None-
theless, HbA1c has important limitations
(1), and it is possible that nontraditional
serum markers of glycemia, such as fruc-
tosamine, glycated albumin, and 1,5-
anhydroglucitol (1,5-AG), may have
added clinical utility. Glycated albumin
and fructosamine reﬂect the modiﬁcation
of serum proteins by glucose and are
markers of endogenous glucose exposure
overtheprior2to4weeks,i.e.,extending
beyond the half-life of albumin and some
other serum proteins. 1,5-AG is a marker
of glycemia-induced glycosuria, since re-
absorption of ﬁltered 1,5-AG in the prox-
imal tubule is competitively inhibited by
glucose (2,3). Lower serum 1,5-AG re-
ﬂects high circulating glucose and the
occurrence of glycosuria over the previ-
ous 1 to 2 weeks (3,4). These serum
markers may be useful as adjuncts to
HbA1c to provide information on short-
term (e.g., 2–4 weeks) glycemic control
andglycemicexcursions,and/orformon-
itoring glycemic control when interpre-
tation of HbA1c is problematic (e.g., in
t h ep r e s e n c eo fh e m oglobinopathies,
iron deﬁciency, and other anemias).
However, few studies have examined
the association of serum glycemic mark-
erswithcomplications(5).Theobjective
of this study was to characterize and
compare the associations of nontradi-
tional (fructosamine, glycated albumin,
1,5-AG) and standard (fasting glucose,
HbA1c) glycemic markers with common
microvascular conditions associated
with diabetes in a general population.
RESEARCH DESIGN AND
METHODS
Study population
We conducted a cross-sectional study of
participantsfromtheAtherosclerosisRisk
in Communities (ARIC) Study who par-
ticipated in the ARIC Carotid MRI
(CARMRI) substudy. The ARIC Study is
an ongoing prospective cohort study of
15,792 black and white adults originally
enrolledbetween1987and 1989(6).Just
over 2,000 participants from the original
cohort, now aged 60–84 years, were re-
cruited into the CARMRI substudy in
2004and2005usingastratiﬁedsampling
plan (7). In addition to the MRI examina-
tion, trained technicians performed a
comprehensive clinical examination, ob-
tained blood specimens, and conducted
an interview to obtain information on
health status and risk factors. Our study
sample was limited to 1,600 participants
(227 with a history of diabetes and 1,323
without) after excluding those who fasted
lessthan8h(N=20)orwhoweremissing
variables of interest (N = 402). An addi-
tional 51 participants had missing or un-
gradable retinal photographs and were
further excluded from our analyses of ret-
inopathy.
Institutional review boards at each
clinical site approved the study protocol,
and written informed consent was ob-
tained from all participants.
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Pathophysiology/Complications
ORIGINAL ARTICLEGlycemic markers
HbA1c was measured from whole-blood
samples as part of the original CARMRI
protocol using the Tina-quant II method
(Roche Diagnostics, Basel, Switzerland)
implemented on a Roche Hitachi 911
Analyzer. This method is aligned to the
Diabetes Control and Complications Trial
assay. In 2009, we measured glycated
albumin (Asahi Kasei Lucica GA-L; Asahi
Kasei Pharma Corporation, Tokyo,
Japan)—expressed as a percentage of
totalserumalbumin,fructosamine(Roche
Diagnostics), and 1,5-AG (GlycoMark,
Winston-Salem, NC) from stored serum
specimens using a Roche Modular P800
system. The interassay coefﬁcients of var-
iation (CVs) were 2.7% for glycated albu-
min, 3.7% for fructosamine, and 4.8% for
1,5-AG.
Outcomes
We focused on three microvascular con-
ditions: chronic kidney disease, albumin-
uria, and retinopathy. Serum creatinine
was measured using a Roche enzymatic
assay, calibrated by the manufacturer to
be traceable to reference method proce-
dures (standard creatinine). The glomer-
ular ﬁltration rate (GFR) was estimated
using the four-variable Modiﬁcation of
Diet in Renal Disease (MDRD) Study
formula re-expressed to use standard
creatinine and reported in milliliters per
minute per 1.73 m
2 (8–10). People with
estimated GFR (eGFR) below 60 mL/min/
1.73 m
2 were considered to have chronic
kidney disease (11). Urine albumin and
creatinine were measured from random
spot urine collected at the CARMRI visit
using a clean-catch technique and sterile
containers. We deﬁned albuminuria as a
urine albumin-to-creatinine ratio of 30
mg/g or higher and conducted sensi-
tivity analyses excluding those people
with macroalbuminuria (albumin-to-
creatinine ratio $300 mg/g). Retinal
photographs were taken following a stan-
dardized protocol that has been previously
documented (12). Brieﬂy, after 5 min of
darkadaptation,a nonmydriatic45-degree
r e t i n a lp h o t o g r a p hc e n t e r e do nt h eo p t i c
discandmaculawastakenofonerandomly
selected eye. Trained readers masked to
participant information evaluated each of
the photographs. We deﬁned retinopathy
(moderate to severe) as a severity score
greater than or equal to 35 according to a
modiﬁcation of the Airlie House classiﬁ-
cation system, as used in the Early Treat-
ment DiabeticRetinopathy Study (ETDRS)
(12,13).
Other variables of interest
Other measurement protocols in ARIC
CARMRI were identical to those imple-
mented in the original ARIC Study (7).
Blood samples were assayed for total
and high-density lipoprotein cholesterol,
glucose, and high-sensitivity C-reactive
protein using conventional techniques.
BMIwascomputedfrommeasuredheight
and weight. Information on cigarette
smoking and alcohol consumption was
elicited during the interview. Resting sys-
tolic blood pressure (average of two read-
ings) was measured using a random-zero
sphygmomanometer. Participants were
asked to bring current medications to
the visit, and information on cholesterol-
andbloodpressure-loweringmedications
was also obtained during the interview.
Diabetes history was determined by use
of glucose-lowering medications or a
self-reported physician diagnosis of dia-
betes. Previous history of coronary heart
diseaseincludedareportedhistoryofcor-
onary heart disease and/or an adjudicated
coronaryheartdiseaseeventduringactive
surveillance up to the CARMRI visit (14).
Statistical analysis
Characteristics of the study population
were calculated overall and by history of
diagnosed diabetes. We also compared
mean values of each glycemic marker
by categories of important risk factors
separately in people with and without a
history of diagnosed diabetes. We used
multivariablelogisticregressionmodelsto
assess the independent association of each
glycemic marker with microvascular con-
ditions: chronic kidney disease, albumin-
uria, and retinopathy. For comparability,
we divided the population into diabetes-
speciﬁc tertiles of each glycemic marker.
Because1,5-AG islowered whilethe other
glycemic markers are increased in the
setting of hyperglycemia, we transformed
1,5-AG to 1/1,5-AG for consistency in
interpretation of the diabetes-speciﬁc
tertiles (the ranking of individuals is un-
changed by inverse transformation).
Model 1 was adjusted for age (in years),
sex,educationlevel(lessthanhighschool;
high school or equivalent; some college
or higher), family history of diabetes,
previoushistoryofcoronaryheartdisease,
averagesystolicbloodpressure(inmmHg),
use of blood pressure medication, use of
cholesterol-lowering medication, total
cholesterol concentration (in mg/dL),
HDL cholesterol concentration (in mg/dL),
smoking status (current; former; never),
BMI (in kg/m
2), and high-sensitivity
C-reactive protein concentration (in mg/L).
Because there is ongoing debate regarding
the need for correction of fructosamine
assays for serum albumin (15), models
of fructosamine were additionally ad-
justed for serum albumin concentration
Table 1—Participant characteristics overall and by diabetes history
All Diabetes No diabetes
N 1,600 277 1,323
Age (years) 70.4 (0.2) 70.3 (0.4) 70.4 (0.2)
Men (%) 43.1 (1.5) 48.2 (3.9) 42.1 (1.7)
Black (%) 18.7 (0.3) 32.0 (1.4) 16.3 (0.3)
Education (%)
Less than high school 15.0 (1.0) 19.0 (2.6) 14.3 (1.1)
High school or equivalent 44.9 (1.6) 49.0 (3.8) 44.2 (1.7)
College or above 40.1 (1.5) 32.0 (3.6) 41.5 (1.7)
Family history of diabetes (%) 23.5 (1.3) 37.4 (3.7) 21.0 (1.4)
Previous history of coronary heart disease (%) 9.7 (0.8) 16.4 (2.6) 8.4 (0.9)
Blood pressure medication use (%) 64.7 (1.5) 85.4 (3.0) 60.9 (1.7)
Cholesterol-lowering medication use (%) 44.9 (1.5) 70.4 (3.5) 40.3 (1.7)
Smoking status (%)
Current 7.9 (0.8) 7.6 (2.1) 7.9 (0.9)
Former 41.4 (1.5) 46.4 (3.8) 40.5 (1.7)
Never 50.8 (1.6) 46.0 (3.7) 51.6 (1.7)
Systolic blood pressure (mmHg) 126.3 (0.6) 127.0 (1.5) 126.1 (0.6)
BMI (kg/m
2) 28.9 (0.2) 31.6 (0.5) 28.4 (0.2)
Total cholesterol (mg/dL) 193.0 (1.3) 173.4 (3.4) 196.6 (1.3)
HDL cholesterol (mg/dL) 50.0 (0.5) 44.4 (1.0) 51.0 (0.5)
C-reactive protein (mg/L) 1.9 [1.0,4.4] 1.7 [0.9,3.6] 2.0 [1.0,4.4]
Data are weighted means (SE), weighted median [IQR], or weighted proportions (SE).
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Selvin and AssociatesTable 2—Mean levels of glycemic markers by demographic and clinical characteristics in participants without a history of diabetes
(n = 1,323)
Glycated
albumin (%)
Fructosamine
(mmol/L)
1,5-AG
(mg/mL)
HbA1c
(%)
Fasting glucose
(mg/dL)
Overall 13.6 (0.05) 230.1 (0.7) 17.9 (0.2) 5.6 (0.02) 102.7 (0.5)
Age (years)
,65 13.3 (0.1) 227.5 (0.9) 19.1 (0.6) 5.6 (0.04) 103.0 (1.5)
$65 13.7 (0.05) 230.7 (0.8) 17.6 (0.8) 5.6 (0.02) 102.6 (0.7)
P value 0.01 0.12 0.01 0.47 0.83
Sex
Women 13.6 (0.1) 229.8 (0.9) 17.3 (0.3) 5.7 (0.03) 101.0 (0.7)
Men 13.5 (0.1) 230.6 (1.1) 18.6 (0.4) 5.6 (0.02) 105.1 (0.9)
P value 0.34 0.58 0.005 0.02 ,0.001
Race
White 13.4 (0.1) 228.5 (0.8) 18.0 (0.3) 5.6 (0.1) 102.0 (0.6)
Black 14.6 (0.1) 238.6 (0.2) 17.1 (0.4) 5.9 (0.1) 106.3 (1.1)
P value ,0.001 ,0.001 0.0627 ,0.001 0.001
Education
,12 years 13.9 (0.1) 234.2 (1.8) 18.8 (0.5) 5.7 (0.1) 104.1 (1.5)
High school or equivalent 13.7 (0.1) 231.1 (1.1) 17.8 (0.4) 5.6 (0.02) 103.3 (0.9)
Tertiary education 13.4 (0.1) 227.8 (1.1) 17.6 (0.3) 5.6 (0.03) 101.6 (0.7)
P value for trend 0.001 0.001 0.11 0.24 0.07
Family history of diabetes
No 13.6 (0.6) 229.3 (0.8) 18.0 (0.2) 5.6 (0.02) 102.1 (0.6)
Yes 13.8 (0.1) 233.4 (1.8) 17.4 (0.5) 5.7 (0.04) 105.1 (1.3)
P value 0.12 0.04 0.33 0.52 0.04
History of coronary heart disease
No 13.6 (0.1) 230.1 (0.8) 17.8 (0.2) 5.6 (0.02) 102.8 (0.6)
Yes 13.5 (0.1) 230.1 (2.2) 18.2 (0.8) 5.5 (0.04) 101.8 (1.4)
P value 0.48 0.98 0.64 0.01 0.55
Hypertension
No 13.5 (0.1) 228.5 (1.1) 17.9 (0.4) 5.6 (0.03) 100.0 (0.9)
Yes 13.6 (0.1) 230.9 (0.9) 17.8 (0.3) 5.7 (0.02) 104.0 (0.7)
P value 0.24 0.10 0.80 0.004 ,0.001
Hypercholesterolemia
No 13.7 (0.1) 230.2 (1.0) 17.9 (0.3) 5.6 (0.3) 102.0 (0.8)
Yes 13.5 (0.1) 230.1 (1.0) 17.8 (0.3) 5.7 (0.2) 103.5 (0.8)
P value 0.03 0.94 0.76 0.21 0.21
Smoking
Current 13.0 (0.1) 222.5 (2.4) 19.6 (0.9) 5.6 (0.05) 101.0 (2.2)
Former 13.5 (0.1) 230.5 (1.2) 17.9 (0.4) 5.6 (0.03) 102.9 (0.9)
Never 13.7 (0.7) 231.0 (1.0) 17.6 (0.3) 5.7 (0.03) 102.8 (0.7)
P value for trend ,0.001 0.02 0.05 0.31 0.64
BMI (kg/m
2)
,25 14.0 (0.1) 235.1 (1.2) 16.5 (0.5) 5.6 (0.05) 98.3 (1.1)
25 to ,30 13.5 (0.1) 230.0 (1.0) 18.0 (0.3) 5.6 (0.02) 101.7 (0.8)
$30 13.4 (0.1) 226.6 (1.4) 18.7 (0.4) 5.7 (0.03) 107.4 (1.0)
P value for trend ,0.001 ,0.001 0.001 0.005 ,0.001
C-reactive protein (mg/L)
,1 13.8 (0.1) 233.5 (1.3) 17.5 (0.4) 5.6 (0.05) 100.0 (1.0)
1t o,3 13.4 (0.1) 229.0 (1.2) 17.7 (0.4) 5.6 (0.03) 101.3 (0.9)
$3 13.7 (0.1) 229.0 (1.3) 18.3 (0.4) 5.7 (0.02) 106.0 (0.9)
P value for trend 0.64 0.02 0.18 0.14 ,0.001
Chronic kidney disease (eGFR ,60 mL/min/1.73 m
2)
No 13.5 (0.1) 229.0 (0.8) 17.8 (0.2) 5.6 (0.02) 102.5 (0.6)
Yes 13.9 (0.1) 235.1 (1.9) 18.0 (0.6) 5.7 (0.05) 103.5 (1.5)
P value 0.01 0.003 0.82 0.03 0.56
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Serum glycemia and microvascular conditions(in g/dL). Model 2 was adjusted for all
variables in model 1 plus HbA1c (in per-
centages). All analyses were weighted by
t h ei n v e r s eo ft h es a m p l ef r a c t i o n si nt h e
s t u d ys a m p l i n gs t r a t au s i n gm e t h o d sf o r
the analysis of complex sample survey
design data (7).
All reported P values are two-sided,
and P values ,0.05 were considered sta-
tistically signiﬁcant.
RESULTS—T h ep r e v a l e n c ee s t i m a t e s
for each the microvascular conditions
in people with a history of diabetes were
as follows: 27.7% had chronic kidney
disease, 23.0% had albuminuria (4.1%
macroalbuminuria), and 11.4% had reti-
nopathy. In people without a history of
diabetes, the corresponding prevalence
estimates were 18.1% for chronic kidney
disease, 10.4% for albuminuria (0.9%
macroalbuminuria), and 2.8% for reti-
nopathy. Demographic and clinical vari-
ables also differed substantially by diabetic
status (Table 1). People with a history of
diagnosed diabetes were more likely to be
m e na n dA f r i c a nA m e r i c a na n dh a v ea
high-school education or less and a family
history of diabetes compared with people
in the study sample with no history of di-
abetes.Peoplewithdiagnoseddiabetesalso
had poorercardiovascular riskproﬁles and
were less likely to be current smokers.
Mean levels of the different glycemic
markers differed substantially by dia-
betic status (Tables 2 and 3). The mean
glycated albumin, fructosamine, 1,5-AG,
HbA1c, and fasting glucose values in
people without a history of diagnosed
diabetes were 13.6%, 230.1 mmol/L,
17.9 mg/mL, 5.6%, and 102.7 mg/dL, re-
spectively. In people with diabetes, the
corresponding means were 17.8%, 274.3
mmol/L, 12.6 mg/mL, 6.7%, and 140.1
mg/dL, respectively. Table 2 reveals sub-
stantial differences in the associations of
each marker with basic demographic and
clinical characteristics. In people without
diabetes, glycated albumin was signiﬁ-
cantly higher and 1,5-AG was lower in
people aged 65 years and older compared
withpeople,65yearsofage;fructosamine,
HbA1c, and fasting glucose did not differ
by age group. Whereas fructosamine and
glycated albumin appeared similar by
sex, men had signiﬁcantly higher 1,5-AG,
higher HbA1c, and higher fasting glucose.
BMI was signiﬁcantly associated with all
markers but not in the expected direction
for glycated albumin or fructosamine,
which were both lower, and for 1,5-AG,
which was higher, at higher BMI levels.By
contrast, HbA1c and fasting glucose were
both signiﬁc a n t l yh i g h e ra th i g h e rB M I
levels. Levels of glycated albumin and
fructosamine were also signiﬁcantly
higher in people who have never smoked
comparedwith former orcurrent smokers.
HbA1cand fastingglucose were not signif-
icantlydifferentacrosscategoriesofsmok-
ing. Substantial racial differences were
seen across all markers in both people
with and without diabetes, with African
Americans having higher levels of glyce-
miaasindicatedbyeach marker, although
the results were not statistically signiﬁcant
for 1,5-AG in people with or without di-
abetes. Fasting glucose was higher, but
not statistically signiﬁcantly so, in diabetic
African Americans compared with whites
(P value = 0.13). In these unadjusted anal-
yses, we observed associations between
some of the glycemic markers and preva-
lent chronic kidney disease, albuminuria,
and retinopathy, but these results were
variable across the different measures of
hyperglycemia (Tables 2 and 3).
In our adjusted logistic regression
models of microvascular outcomes in
the total population comparing diabetes-
speciﬁc tertiles of each glycemic marker,
we observed signiﬁcant positive trends in
the associations of each marker with
albuminuria and retinopathy (Fig. 1 and
Supplementary Table 1), even after ac-
counting for demographic, clinical, and
lifestyle factors. The associations with
chronic kidney disease were similar in
magnitude and direction but not signiﬁ-
cant for all markers: glycated albumin
(Ptrend=0.005),fructosamine(Ptrend=
0.003),andHbA1c(P trend= 0.005) were
signiﬁcantly and positively associated
with the presence of chronic kidney dis-
ease, but 1/1,5-AG (P t r e n d=0 . 7 2 )a n d
fasting glucose (P trend = 0.66) were not.
After further adjustment for HbA1c in
these models (Supplementary Fig. 1 and
SupplementaryTable2),weobservedsig-
niﬁcant trends in the associations of gly-
catedalbuminwithretinopathy(Ptrend=
0.01)andborderlinesigniﬁcanttrendsfor
chronic kidney disease (P t r e n d=0 . 0 5 )
and albuminuria (P trend = 0.07). After
adjustment for HbA1c,p o s i t i v et r e n d s
for fructosamine also remained signiﬁ-
cant for chronic kidney disease (P trend =
0.03) and retinopathy (P trend = 0.02)
and borderline signiﬁcant for albumin-
uria (P trend = 0.05). 1/1,5-AG remained
signiﬁcantly positively associated with al-
buminuria (P trend = 0.04) but not with
chronickidneydisease(Ptrend=0.63)or
retinopathy (P trend = 0.42). Overall
trends for fasting glucose were not signif-
icantforanyoutcomeafteradjustmentfor
HbA1c (all P trends .0.3); however, the
lowest tertile of fasting glucose in people
with diagnosed diabetes was signiﬁcantly
associated with chronic kidney disease
and albuminuria. HbA1c, by contrast, was
no longer statistically signiﬁcantly associ-
ated with any of these outcomes in these
fully adjusted models (all P values .0.05).
CONCLUSIONS—Wecomparednon-
traditional serum markers of glycemia
(glycated albumin, fructosamine, and
Table 2—Continued
Glycated
albumin (%)
Fructosamine
(mmol/L)
1,5-AG
(mg/mL)
HbA1c
(%)
Fasting glucose
(mg/dL)
Albuminuria
No 13.5 (0.05) 229.4 (0.7) 18.0 (0.2) 5.6 (0.02) 102.2 (0.6)
Yes 14.1 (0.2) 236.3 (2.6) 16.7 (0.6) 5.8 (0.1) 107.2 (2.0)
P value 0.01 0.01 0.05 0.02 0.02
Retinopathy*
No 13.6 (0.05) 229.8 (0.7) 17.9 (0.2) 5.6 (0.02) 102.7 (0.6)
Yes 14.2 (0.3) 235.7 (5.8) 17.1 (1.4) 5.9 (0.2) 99.4 (2.3)
P value 0.03 0.32 0.59 0.21 0.16
Data are weighted means (SE). *n = 1,284.
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Glycated
albumin (%)
Fructosamine
(mmol/L)
1,5-AG
(mg/mL)
HbA1c
(%)
Fasting glucose
(mg/dL)
Overall 17.8 (0.3) 274.3 (3.4) 12.6 (0.6) 6.7 (0.1) 140.1 (3.0)
Age (years)
,65 18.7 (0.9) 284.2 (8.8) 10.7 (1.4) 7.2 (0.3) 151.6 (7.0)
$65 17.6 (0.3) 272.4 (3.7) 12.9 (0.6) 6.7 (0.1) 137.8 (3.3)
P value 0.28 0.23 0.13 0.06 0.08
Sex
Women 17.7 (0.4) 270.0 (4.7) 13.2 (0.9) 6.8 (0.1) 145.6 (4.4)
Men 17.9 (0.5) 279.0 (5.2) 11.9 (0.8) 6.7 (0.1) 134.1 (4.1)
P value 0.66 0.22 0.24 0.71 0.06
Race
White 16.8 (0.3) 264.6 (3.7) 13.3 (0.7) 6.5 (0.1) 136.6 (3.3)
Black 19.9 (0.7) 295.1 (7.3) 11.1 (0.9) 7.2 (0.2) 147.4 (6.3)
P value ,0.001 ,0.001 0.08 ,0.001 0.13
Education
,12 years 19.3 (0.8) 296.4 (9.6) 11.0 (1.2) 7.2 (0.2) 147.6 (7.5)
High school or equivalent 17.5 (0.4) 269.1 (5.0) 13.5 (0.9) 6.6 (0.1) 136.5 (4.5)
Tertiary education 17.4 (0.5) 269.2 (5.2) 12.2 (0.8) 6.7 (0.1) 141.0 (4. 8)
P value for trend 0.06 0.03 0.61 0.05 0.60
Family history of diabetes
No 17.8 (0.4) 275.6 (4.6) 13.1 (0.7) 6.7 (0.1) 136.4 (3.7)
Yes 17.8 (0.5) 272.2 (5.5) 11.8 (1.0) 6.7 (0.1) 146.2 (5.1)
P value 0.97 0.65 0.29 0.99 0.12
History of coronary heart disease
No 17.8 (0.3) 273.9 (3.7) 12.7 (0.6) 6.7 (0.1) 140.3 (3.3)
Yes 17.9 (0.9) 276.4 (9.3) 12.1 (1.5) 6.9 (0.3) 138.9 (8.2)
P value 0.93 0.81 0.70 0.44 0.87
Hypertension
No 17.0 (1.0) 263.0 (10.1) 12.7 (1.5) 6.5 (0.2) 139.0 (7.5)
Yes 17.9 (0.3) 275.9 (3.6) 12.6 (0.6) 6.8 (0.1) 140.2 (3.3)
P value 0.36 0.24 0.94 0.19 0.88
Hypercholesterolemia
No 19.4 (0.7) 291.3 (8.4) 11.3 (1.1) 7.0 (0.2) 148.6 (6.4)
Yes 17.3 (0.3) 268.6 (3.6) 13.0 (0.7) 6.7 (0.1) 137.2 (3.4)
P value 0.01 0.02 0.16 0.06 0.12
Smoking
Current 18.1 (1.0) 263.9 (12.1) 12.2 (2.1) 6.6 (0.2) 140.1 (8.5)
Former 17.6 (0.5) 274.5 (5.5) 11.6 (0.7) 6.7 (0.1) 136.7 (4.1)
Never 18.0 (0.4) 275.9 (4.9) 13.7 (1.0) 6.8 (0.1) 143.5 (5.0)
P value for trend 0.78 0.49 0.17 0.65 0.39
BMI (kg/m
2)
,25 19.5 (0.8) 294.6 (10.9) 11.7 (1.4) 6.6 (0.1) 141.8 (7.6)
25 to ,30 16.9 (0.5) 265.3 (6.3) 11.7 (0.8) 6.6 (0.2) 127.5 (4.7)
$30 17.8 (0.4) 273.7 (4.4) 13.2 (0.9) 6.9 (0.1) 145.5 (4.2)
P value for trend 0.33 0.26 0.24 0.09 0.18
C-reactive protein (mg/L)
,1 17.6 (0.4) 275.4 (5.1) 12.4 (1.0) 6.5 (0.1) 135.9 (5.5)
1t o,3 17.8 (0.5) 274.6 (5.9) 11.9 (0.9) 6.7 (0.1) 137.0 (4.6)
$3 17.9 (0.6) 273.0 (6.9) 13.6 (1.1) 7.0 (0.2) 148.2 (5.7)
P value for trend 0.69 0.79 0.44 0.02 0.11
Chronic kidney disease (eGFR ,60 mL/min/1.73 m
2)
No 17.9 (0.3) 275.1 (4.0) 11.9 (0.6) 6.8 (0.1) 141.4 (3.4)
Yes 17.6 (0.7) 272.3 (7.4) 14.3 (1.4) 6.6 (0.1) 136.7 (6.5)
P value 0.76 0.74 0.13 0.21 0.53
Albuminuria
No 17.3 (0.3) 268.6 (3.7) 13.0 (0.7) 6.7 (0.1) 139.3 (3.0)
Yes 19.4 (0.7) 293.4 (8.8) 11.1 (1.1) 7.0 (0.2) 142.7 (7.9)
P value 0.01 0.01 0.16 0.04 0.69
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in clinical practice (fasting glucose and
HbA1c) in their associations with micro-
vascular conditions. We observed intrigu-
ing differences in the associations of each
glycemic marker with basic demographic
and clinical characteristics. To the extent
that cross-sectional risk factor associa-
tions differ, this may indicate that the
different glycemic markers contribute in-
dependent clinical information and may
enhance the prognostic value of standard
glycemic markers. Indeed, we observed
qualitative differences in the associations
of the various glycemic markers with
smoking status and BMI. There is evi-
dence that both smoking and higher
levels of adiposity can lead to a state of
increase oxidative stress because of in-
creased reactive oxygen species (16).
Our data may indicate that circulating
concentrations of glycated albumin and
fructosamine are differentially affected
bythesestatesofoxidantstresscompared
with traditional glycemic markers. It is
also possible that glycated albumin, fruc-
tosamine, and 1,5-AG are more strongly
affected by postprandial glycemic excur-
sions compared with HbA1c,c o n t r i b u t i n g
to the observed differences (17,18).
After adjustment for confounding
factors, we found that glycated albumin,
fructosamine, and HbA1c were similarly
positively associated with prevalent
chronic kidney disease, albuminuria,
and retinopathy. Fasting glucose and
1,5-AG were associated with albuminuria
and retinopathy but not chronic kidney
disease.Theassociationsofglycatedalbu-
minandfructosaminewithmicrovascular
outcomes were evident even after adjust-
ment for HbA1c, suggesting that these se-
rum markers of glycemic control may
contribute independent risk information.
The less robust results for fasting glucose,
particularly among people with a diagno-
sis of diabetes in the upper two tertiles of
the glycemic markers, may partially re-
ﬂect that nearly all people with diagnosed
diabetes reported current use of glucose-
lowering medication(s).
Fructosamine is often used in clinical
practice to monitor glycemic control in
people with conditions that interfere with
Table 3—Continued
Glycated
albumin (%)
Fructosamine
(mmol/L)
1,5-AG
(mg/mL)
HbA1c
(%)
Fasting glucose
(mg/dL)
Retinopathy*
No 17.3 (0.3) 268.6 (3.4) 12.8 (0.6) 6.7 (0.1) 136.9 (3.0)
Yes 20.9 (1.3) 306.8 (14.4) 11.4 (1.8) 7.2 (0.3) 163.6 (12.7)
P value 0.01 0.01 0.45 0.09 0.04
Data are weighted means (SE). *n =2 6 5 .
Figure1—Adjustedoddsratios(95%CI)formicrovascularconditionsbydiabetes-speciﬁctertilesofeachglycemicmarker;oddsratiosareadjusted
forage,sex,educationlevel,familyhistoryofdiabetes,previouscoronaryheartdisease,useofbloodpressuremedication,useofcholesterol-lowering
medication, smoking status, BMI, systolic blood pressure, total cholesterol, HDL cholesterol, and C-reactive protein. Fructosamine models are
additionally adjusted for serum albumin. Chronic kidney disease was deﬁned as an estimated glomerular ﬁltration rate ,60 mL/min/1.73 m
2.
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Selvin and Associatesthe interpretation or measurements of
HbA1c, such as the presence of some he-
moglobin variants, certain anemias, dial-
ysis treatment, or other conditions that
cause hemolysis or otherwise alter
erythrocyte turnover. The colorometric
process of the fructosamine assay is chal-
lenging to perform, and there is ongoing
debate regarding the need for correction
of fructosamine assays for serum albumin
concentrations (15,19). For this reason,
we adjusted all fructosamine analyses for
serum albumin concentration. An addi-
tional general concern regarding fructos-
amine is the ﬂuctuating concentrations of
other serum proteins that may affect the
assay result. Our study demonstrates ex-
cellent reliability of this fructosamine as-
s a yw i t ha ni n t e r a s s a yC V=3 . 7 %a n d
signiﬁcant associations of fructosamine
with microvascular outcomes. The gly-
cated albumin assay examined here is a
newer automated assay not yet approved
for clinical use in the U.S. but which also
showed excellent laboratory perfor-
mance, interassay CV = 2.7%. In this as-
say, glycated albumin is expressed as a
percentage of total serum albumin (20),
simplifying the interpretation of the re-
sult. Indeed, additional adjustment for
serumalbumininouranalysesofglycated
albumin and microvascular outcomes did
not appreciably alter our results (data not
shown). It has also been suggested that
glycated albumin itself, beyond its role
as marker of hyperglycemia, may contrib-
ute directly to the development of com-
plications (21), including diabetic
nephropathy (22,23).
1,5-AG is a novel marker of glycemia,
reﬂecting a nonglycation-dependent bi-
ological process: it is thought to reﬂect
hyperglycemic excursions over the past 1
to 2 weeks (4). Urinary excretion of
1,5-AG is accelerated in the setting of hy-
perglycemia and high circulating concen-
trations of glucose (exceeding the renal
threshold) will cause serum 1,5-AG con-
centrationstofall(24).Theattractiveness
of 1,5-AG is that it may capture addi-
tional information on glycemic excur-
sions not reﬂected in fasting glucose,
HbA1c, fructosamine, or glycated albu-
min values (17). However, it is unclear
whether concentrations of 1,5-AG may
be altered in the presence of moderately
impaired kidney function or albumin-
uria, raising questions regarding reverse
causality.
Limitationsthatshouldbeconsidered
in the interpretation of these data include
the cross-sectional design; we could not
determinethetemporalityoftheobserved
associations, and we had only a limited
number of people with known diabetes
(N = 277). Sample size limitations ex-
cluded the possibility of comprehen-
sive examination of other subgroups.
The direct comparison between results
for glycated albumin versus those for
fructosamine remains challenging. To
our knowledge, there is no reference
method procedure for glycated albumin
or for those measurements related to gly-
cation of proteins circulating in blood.
Thus, the fructosamine assay (a colori-
metric assay based on ketoamines reduc-
ing nitrotetrazolium-blue) does not
directly relate to the measure of glycated
albumin (an enzymatic method using ke-
toamine oxidase and an albumin-speciﬁc
protease),anddifferencesinresultsacross
these measurements are difﬁcult to inter-
pret in the context of an epidemiologic
study. Important strengths of this study
includethecomparisonofapanelofnovel
serum markers with those that are used in
standard practice, the community-based
biracial sample of peoplewith and without
diabetes, which allowed us to assess these
epidemiologic associations across the full
range of glycemia. Additional advantages
to conducting this study nested within
the ARIC cohort included the rigorous
measurement of known risk factors for
diabetes using standardized protocols
and assessment of multiple microvascu-
lar conditions. We observed excellent
laboratory performance for all assays.
Physicians typically use multiple bio-
markers to assess the metabolic status of
their patients, but the additional clinical
utility of serum glycemic markers beyond
standard measures of glycemia is unclear.
In our cross-sectional analyses, two se-
rum markers of glycemia—glycated albu-
min and fructosamine—were as strongly,
or more strongly, associated with micro-
vascular conditions as HbA1c. Our results
suggest that serum glycemic markers,
particularlyglycatedalbuminand/orfruc-
tosamine, may add important clinical
information for the identiﬁcation of peo-
ple at risk for microvascular conditions
and possibly the management of diabetes.
Measurement of HbA1c requires a whole-
blood sample; sometimes relatively labor-
intensiveassaymethodologiesandconcerns
havebeenraisedabouttheperformanceof
HbA1cincertainsubpopulations(25).The
markers examined here can be measured
reliably in serum using standard, auto-
mated methods and may be useful in set-
tings where whole blood is not available.
Whether serum glycemic markers might
complement or outperform HbA1c in
terms of long-term predictive value re-
quires further investigation.
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